Bevacizumab must be specially prepared for intraocular use.
Ilias
I
Georgalas
Dimitris
D
Papaconstantinou
Theodore
T
Paraskevopoulos
Chryssanthi
C
Koutsandrea
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006801:Humans; D057135:Wet Macular Degeneration / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized